DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2236716/davita-dva-expands-operational-footprint-via-new-agreement?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236716 Mar 06, 2024 - DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America. 0

https://www.zacks.com/stock/news/2240686/buy-5-medical-devices-stocks-for-a-stable-portfolio-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240686 Mar 14, 2024 - We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW. 0

https://www.zacks.com/stock/news/2249369/tenet-thc-divests-six-hospitals-sustains-divestiture-spree?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249369 Apr 02, 2024 - Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden. 0

https://www.zacks.com/commentary/2255364/3-medical-instruments-stocks-to-buy-amid-improving-industry-trends?cid=CS-ZC-FT-industry_outlook-2255364 Apr 15, 2024 - The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges. 0

https://www.zacks.com/stock/news/2219585/dexcom-dxcm-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2219585 Feb 01, 2024 - DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2220910/curious-about-dexcom-dxcm-q4-performance-explore-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2220910 Feb 05, 2024 - Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. 0

https://www.zacks.com/stock/news/2223683/dexcom-dxcm-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2223683 Feb 08, 2024 - The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.fool.com/earnings/call-transcripts/2024/02/08/dexcom-dxcm-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 08, 2024 - DXCM earnings call for the period ending December 31, 2023. 0

https://www.fool.com/investing/2024/02/10/2-no-brainer-healthcare-stocks-to-buy-right-now/?source=iedfolrf0000001 Feb 10, 2024 - Companies in the healthcare industry tend to generate returns in a wide range of market environments. 0

https://www.zacks.com/stock/news/2231836/clearpoint-neuro-clpt-gets-fda-s-nod-for-new-software?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2231836 Feb 26, 2024 - ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain. 0